|
LDA NEWS & UPDATES
October 31, 2022
| |
The Lyme Disease Association’s YouTube channel features a recent video of LDA President, Pat Smith, who presented a webinar to NE public health officials on an up-to-date look at the different ticks and tick-borne diseases across the U.S. and in Nebraska at the request of the Winnebago Public Health Nursing Department. The webinar was also supported by Winnebago Public Health Department and funded by a grant from the National Indian Health Board Infectious Disease Control to the Nursing Department. Read more. | |
Pat Smith, 2022: Overview of Ticks and TBD in US & Nebraska | | |
|
Cherie L. Marvel, et al., published “A multimodal neuroimaging study of brain abnormalities and clinical correlates in post treatment Lyme disease” in PLOS ONE on October 26, 2022. The objective was to uncover evidence that may help to explain the cause of cognitive complaints commonly reported amongst patients with post treatment Lyme disease (PTLD). Read more. | | |
|
The 7th Annual LymeMIND Virtual Conference is scheduled for Saturday, November 5, 2022, from 1:00-4 PM ET followed by a 30-minute live question and answer session. LymeMind, Icahn School of Medicine at Mount Sinai, is a collaborative network of researchers, patients, physicians, and sponsors working to advance Lyme disease research. LDA President, Pat Smith, will speak on a panel. Read more. | |
|
The Journal of Clinical Investigation (Strobl, J., et al.) published “Tick feeding modulates the human skin immune landscape to facilitate tick-borne pathogen transmission” on September 27, 2022. In this study, researchers developed a model to evaluate the effects on human skin and blood following tick attachment and Borrelia pathogen transmission.
Observations after an infected tick bite included patterns of immunomodulation that occurred quickly, including increases in neutrophils, a type of white blood cell (leukocytes) that act as your immune system’s first line of defense, as well as an increase in B and T cells in the skin. Read more.
| |
|
Kelley, J.D., et al., published “Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines” in The Journal of American Medical Association (JAMA) on October 11, 2022. Researchers investigated the incidence of severe COVID illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S in adults who were receiving care at Veterans Health Administration (VHA) facilities across the U.S. when Delta and Omicron variants predominated. Read more. | |
| |
|
|
Lorraine Johnson, JD and Elizabeth Maloney, MD published “Access to Care in Lyme Disease: Clinician Barriers to Providing Care” in Healthcare on September 27, 2022. The goal of the study was to determine the barriers that are
encountered by clinicians who provide care for patients with persistent or chronic Lyme disease (PLD/CLD). Prior to this study, patient perspectives had been examined, however, challenges faced by the providers who treat this group of patients had not yet been studied. Read more.
| |
On October 5, 2022, Arizona State University (ASU) News reported an incredible discovery found in the cell membrane of Borrelia burgdorferi that could lead to better therapies for Lyme disease. Karie Behm, an ORISE fellow with the CDC, teamed up with her ASU advisors and mentors, to isolate the membrane protein, BBA57, which is shown to form a complex by binding to copies | |
|
of itself at the membrane surface. Electron microscopy imaging revealed what appears to be a “portal” or “pore” in this protein leading from the cell’s exterior to its interior. This study has been Behm’s passion as she battled Lyme as a young person which took six debilitating years to diagnose. Read more.
LDA Note: Karie Behm (Formerly Robertson) was the only graduate poster presenter at the 2018 LDA conference in RI.
| |
Karie Behm, Ph.D., ORISE Fellow at the CDC | |
Slomski, A. published “Chronic Disease Burden and Financial Problems Are Intertwined” in Journal of American Medical Association (JAMA) on October 4, 2022. The study analyzed data of adults enrolled in a commercially available insurance plan in Michigan including insurance claims that were linked with commercial credit. Read more. | |
|
Top L: female Gulf Coast tick; Top R: male Gulf Coast tick; Bottom L: female American dog tick; Bottom R: male American dog tick. Credit, J. Occi, Ph.D.; LDA Scientific & Professional Advisory Board | |
|
The NJ Department of Health (NJDOH) published the press release “NJDOH Tickborne Disease Update: Rickettsia parkeri rickettsiosis and the Gulf Coast tick” in July, 2022, with the current status of the Gulf Coast tick (Amblyomma maculatum) and the pathogens associated with this vector. The range of this tick has expanded from the southeastern and south-central U.S. to the southern plains and mid Atlantic region of the U.S. as well as many countries throughout Central/South America. Read more.
Read the press release.
| |
|
Funding opportunities for 2023 are now available from the North Central Integrated Pest Management Center (IPM) and the CDC’s National Center for Emerging & Zoonotic Infectious Diseases (NCEZID). The North Central IPM Center is one of four regional centers funded by the U.S. Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) to promote and facilitate the adoption of effective integrated pest management (IPM) strategies.
The NCEZID opportunity is to improve our nation’s ability to combat the growing
| |
|
health threat of vector-borne diseases by building the vector-borne disease prevention and control workforce and improving vector-borne disease prevention control programs, tools, and technologies, and facilitating partnerships. Read more.
More information.
| |
|
Borrelia burgdorferi, Credit: Dave Dorward, PhD, NIH
Read the study.
| |
Dr. Anna Goc, et al., published, “Inhibition of Borrelia Burgdorferi-Induced TLR2-NFκB Canonical Signaling by Gallic Acid through Targeting the CD14+ Adaptor Protein and p65 Molecule” in International Journal of Molecular Sciences on September 20, 2022. With the goal of discovering novel agents that work against B. burgdorferi, the researchers assessed the anti-Borrelia and anti-inflammatory effects of the phenolic compound, gallic acid. Read more. | |
The FDA recently announced that Philips Respironics has recalled over 17 million masks that are used with bilevel positive airway pressure and continuous positive airway pressure machines (aka: PAP, BPAP, CPAP) because they contain magnets which can negatively impact many different metallic medical devices implants, resulting in injury or even death. Read more. | |
|
Tate, L. published “Tulane researchers to develop new Lyme vaccine with lasting protection” in Tulane News on September 28, 2022. Tulane University researchers received National Institutes of Health (NIH) funding in the amount of $1.3 million to test the technology already used as an efficacious Lyme vaccine in canines. Researchers plan to modify this vaccine technology with nano-particles that boost the immune system to determine if safe, long-term, protection can also be achieved in humans. Read more. | |
| |
|
Valneva, a specialty vaccine company, announced in a press release its intent to issue and sell shares of the company on September 28, 2022. The company plans to offer approximately $40 million of its ordinary shares to specific types of investors in the global market. Read more. | |
|
Attention! Mothers Against Lyme First Virtual Meetup
Sponsored by Project Lyme: Nov. 2, 2022, at 8pm ET
Click here for more information.
| |
Your Shopping Can Donate Money to LDA
At No Cost to You!
You can donate to LDA without costing you anything. Shop through smile.amazon.com, and a portion of the sales will then go to LDA for its programs! To sign up for AmazonSmile and have LDA receive a portion of sales click here.
You can also register to become an igive member through igive.com which includes 2326 online stores to shop from. By shopping at the store through igive.com website, LDA will receive a donation. Thank you!
| |
888-366-6611 Toll Free Info Line
| | | | | |
